Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

B SYDNEY, Australia, April 13, 2026 /PRNewswire/ — Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome…
posteditor
posteditor
Articles: 16137

Other News